Cargando…

Editorial: Mechanisms of resistance to the targeted therapy and immunotherapy in cutaneous melanoma

Detalles Bibliográficos
Autores principales:	Premi, Sanjay, Qin, Yong, Ahmad, Nihal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469656/ https://www.ncbi.nlm.nih.gov/pubmed/36110949 http://dx.doi.org/10.3389/fonc.2022.1016901

Ejemplares similares

Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter
por: Thornton, Jessica, et al.
Publicado: (2022)

Role of Melanin Chemiexcitation in Melanoma Progression and Drug Resistance
por: Premi, Sanjay
Publicado: (2020)

Editorial: The role of immunotherapy in melanomas
por: Fateeva, Anna, et al.
Publicado: (2023)

Editorial: The Evolving Role of Immunotherapy in Non-Melanoma Skin Cancers
por: Guida, Michele, et al.
Publicado: (2022)

YY1 Is a Key Player in Melanoma Immunotherapy/Targeted Treatment Resistance
por: Kwiatkowska, Dominika, et al.
Publicado: (2022)

Editorial: Engineered Targeted Cancer Immunotherapies
por: Fantini, Massimo, et al.
Publicado: (2022)

Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma
por: Russo, Irene, et al.
Publicado: (2018)

Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2021)

Construction of immunotherapy-related prognostic gene signature and small molecule drug prediction for cutaneous melanoma
por: Xing, Jiahua, et al.
Publicado: (2022)

Editorial: Tumor microenvironment, inflammation, and resistance to immunotherapies
por: Decock, Julie, et al.
Publicado: (2023)

Editorial: Strategies to overcome tumor evasion and resistance to immunotherapies by targeting immune suppressor cells
por: Saida, Yu, et al.
Publicado: (2023)

Editorial: Personalized immunotherapy for cancer
por: Pasetto, Anna, et al.
Publicado: (2023)

Susceptibility and Resistance Mechanisms During Photodynamic Therapy of Melanoma
por: Li, Xin-Ying, et al.
Publicado: (2020)

Editorial: Targeting tumor vasculature to enhance cancer immunotherapy
por: Yang, Jieying, et al.
Publicado: (2023)

Editorial: Epigenetic Regulation and Tumor Immunotherapy
por: Sun, Hongyin, et al.
Publicado: (2022)

Metabolic Traits in Cutaneous Melanoma
por: Neagu, Monica
Publicado: (2020)

Mechanisms of Cancer Resistance to Immunotherapy
por: Bai, Rilan, et al.
Publicado: (2020)

Editorial: Microenvironment and therapy-resistance in leukemias
por: Friedmann, Rachel, et al.
Publicado: (2023)

Editorial: Cutaneous T-Cell Lymphomas
por: Chung, Catherine G., et al.
Publicado: (2021)

Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma
por: Khaddour, Karam, et al.
Publicado: (2023)

CXC Chemokines as Therapeutic Targets and Prognostic Biomarkers in Skin Cutaneous Melanoma Microenvironment
por: Zhou, Xuezhi, et al.
Publicado: (2021)

Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study
por: Marconcini, Riccardo, et al.
Publicado: (2022)

The Resistance Mechanisms of Lung Cancer Immunotherapy
por: Wang, Fen, et al.
Publicado: (2020)

Editorial: LncRNAs in Cancer Metastasis and Therapy Resistance
por: Ahmad, Aamir, et al.
Publicado: (2021)

Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma
por: Boutros, Andrea, et al.
Publicado: (2021)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
por: Trojaniello, Claudia, et al.
Publicado: (2021)

Editorial: Immunotherapy in Hepatocellular Carcinoma
por: Li, Bin, et al.
Publicado: (2021)

Editorial: Cutaneous B-Cell Lymphomas
por: Alaibac, Mauro, et al.
Publicado: (2020)

Identification of Genes Related to Immune Infiltration in the Tumor Microenvironment of Cutaneous Melanoma
por: Qin, Rujia, et al.
Publicado: (2021)

Melanoma Immunotherapy: Next-Generation Biomarkers
por: Hogan, Sabrina A., et al.
Publicado: (2018)

The Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma
por: Takabe, Piia, et al.
Publicado: (2022)

Prognostic Impact of Autophagy Biomarkers for Cutaneous Melanoma
por: Tang, Diana Y. L., et al.
Publicado: (2016)

Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers
por: Spiliopoulou, Pavlina, et al.
Publicado: (2023)

Editorial: Role of pigmentation in melanoma
por: Brożyna, Anna A., et al.
Publicado: (2022)

Combined Inhibition of Specific Sirtuins as a Potential Strategy to Inhibit Melanoma Growth
por: Singh, Chandra K., et al.
Publicado: (2020)

The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
por: Chu, Gerard J., et al.
Publicado: (2019)

Identification of Therapeutic Targets and Prognostic Biomarkers Among Integrin Subunits in the Skin Cutaneous Melanoma Microenvironment
por: Nurzat, Yeltai, et al.
Publicado: (2021)

Poor Lymphocyte Infiltration to Primary Tumors in Acral Lentiginous Melanoma and Mucosal Melanoma Compared to Cutaneous Melanoma
por: Nakamura, Yoshiyuki, et al.
Publicado: (2020)

Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives
por: Alberti, Andrea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3rh48hi4hean5pqmfg8ddqm72c